REGENXBIO Inc. (RGNX) Trading 9.5% Higher
REGENXBIO Inc. (NASDAQ:RGNX) traded up 9.5% on Tuesday . The stock traded as high as $25.00 and last traded at $24.80. 527,271 shares changed hands during mid-day trading, an increase of 124% from the average session volume of 235,049 shares. The stock had previously closed at $22.65.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded REGENXBIO from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Chardan Capital reissued a “buy” rating and issued a $75.00 price objective (up from $55.00) on shares of REGENXBIO in a report on Tuesday. Evercore ISI assumed coverage on REGENXBIO in a report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, BidaskClub raised REGENXBIO from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.00.
The stock’s market capitalization is $766.17 million. The firm’s 50 day moving average is $20.00 and its 200-day moving average is $19.67.
REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. The business had revenue of $6.56 million during the quarter. On average, analysts predict that REGENXBIO Inc. will post ($2.71) EPS for the current fiscal year.
In related news, CFO Vittal Vasista sold 3,100 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $19.81, for a total transaction of $61,411.00. Following the completion of the transaction, the chief financial officer now owns 108,423 shares in the company, valued at approximately $2,147,859.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kenneth T. Mills sold 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $19.68, for a total value of $127,920.00. Following the transaction, the insider now owns 119,396 shares of the company’s stock, valued at approximately $2,349,713.28. The disclosure for this sale can be found here. Insiders sold a total of 28,740 shares of company stock valued at $563,185 over the last quarter. Company insiders own 17.00% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in RGNX. Teachers Advisors LLC boosted its position in REGENXBIO by 3.4% during the 4th quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $629,000 after purchasing an additional 1,102 shares during the period. Nationwide Fund Advisors boosted its position in REGENXBIO by 7.7% during the 1st quarter. Nationwide Fund Advisors now owns 45,955 shares of the biotechnology company’s stock valued at $887,000 after purchasing an additional 3,280 shares during the period. Acadian Asset Management LLC acquired a new position in REGENXBIO during the 1st quarter valued at approximately $272,000. Strs Ohio boosted its position in REGENXBIO by 93.5% during the 1st quarter. Strs Ohio now owns 32,900 shares of the biotechnology company’s stock valued at $634,000 after purchasing an additional 15,900 shares during the period. Finally, Swiss National Bank boosted its position in REGENXBIO by 30.7% during the 1st quarter. Swiss National Bank now owns 42,600 shares of the biotechnology company’s stock valued at $822,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 73.23% of the company’s stock.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.